Dermaliq Therapeutics utilizes its proprietary hyliQ® technology to enhance the targeted delivery of active ingredients into skin tissues and hair follicles, significantly improving bioavailability without the need for irritating excipients. This approach addresses the challenges of treating dermatological conditions such as alopecia and psoriasis by providing effective topical therapies with reduced systemic side effects.
Funding
Funding not disclosed
DRFounders
Product
Problem
Many topical treatments for dermatological conditions struggle to effectively deliver active ingredients into the skin and hair follicles, limiting their bioavailability and requiring the use of irritating excipients. This delivery barrier hinders the development of effective therapies for conditions like alopecia, psoriasis, and eczema, often leading to suboptimal results and systemic side effects.
Solution
Dermaliq Therapeutics utilizes its proprietary hyliQ® technology to enhance the targeted delivery of active pharmaceutical ingredients (APIs) into the skin and hair follicles. The hyliQ® technology employs novel lipophilic excipients with low viscosity and surface tension to facilitate rapid penetration and the formation of API depots in the associated glands. This approach enables the development of topical drugs and medical skincare products with improved bioavailability and reduced need for skin-irritating preservatives or penetration enhancers. Dermaliq's pipeline focuses on addressing unmet needs in medical dermatology, aesthetics, and follicular diseases, with a focus on localized delivery to minimize systemic side effects.
Target Audience
Dermaliq's primary target audience includes individuals suffering from dermatological conditions such as alopecia, psoriasis, and eczema, as well as medical professionals in dermatology and aesthetics seeking advanced topical treatment options.
Features
- hyliQ® technology: A proprietary drug-delivery platform designed for enhanced cutaneous bioavailability of pharmaceutical actives.
- Targeted delivery: Customization of carrier molecules to enhance penetration into specific skin tissues, glands, or hair follicles.
- DLQ01: A topical formulation of a prostaglandin F2alpha analog in hyliQ® for androgenetic alopecia, currently in Phase 2 clinical development.
- DLQ02: A topical calcineurin inhibitor with anti-inflammatory and immunomodulating properties for alopecia areata, planned for Phase 2a study.
- DLQ03: A topical drug candidate for accelerated wound healing and prevention of secondary skin infections, with Phase 2 data demonstrating faster healing compared to vehicle.
- Liquid formulations: Designed for superior cosmetic properties and ease of use.